Meet Remix™

Remix launched with a vision to transform patient’s lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients.

Our Culture

Remix™ is a scientifically driven organization focused on creating innovative therapies for patients. Each Remixer contributes to our evolving culture, adding their unique perspective towards solving problems. We believe in asking the right questions, prioritizing scientific integrity, and mutual support between teammates.
True to
We are “true to our RNA” and demonstrate the highest levels of scientific integrity and urgency because patients are counting on us. At Remix™, we do the right thing even when no one is watching. We follow the data, are passionate and candid, and honor and deliver on our commitments.
We see magic in the convergence of our culture and our science. We celebrate and encourage diverse perspectives, support one another through successes and failures and believe every employee has a role to play in helping us achieve our vision. We take our work seriously but not ourselves.
We believe courage and curiosity are essential for innovation when the path ahead is unclear. We are boldly driving toward our vision of reprogramming RNA to transform patients’ lives. We push beyond traditional boundaries, ask incisive questions, take calculated risks, learn from failure and innovate relentlessly.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD


Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD


Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.

It's Personal

We are all affected by disease, whether it be through personal experience, a family member, a friend, or even a pet. We are fortunate to be part of the biopharmaceutical industry that strives for the discovery and development of new medicines. We all have a story that makes the work we do at Remix™ so important and we are inspired by responsibility to help patients and their loved ones. Here is a glimpse into our why….
Zaven Kaprielian Sr.

Zaven's Dad

At the age of 84, my dad was diagnosed with progressive dementia, essentially ravaging what should have been his golden years. During this time “with him,” I learned first-hand about the devastating and unexpected impacts and symptoms of AD. These experiences led me to work within an industry setting, where I am proud to be a small part of larger efforts to develop new and effective therapeutics for patients and families in need. I am sure that my dad’s spirit is resting peacefully knowing that we are all hard at work.
Maria Tignor

Maria's Brother

A huge driving force in my career path was my brother, who had Cystic Fibrosis and was in and out of hospitals his whole life, which gave a passion and desire to help find a cure for CF. After taking more specialized courses and working in several other biology roles, I've landed here at Remix, where I have the privilege of working on research that will help patients with different diseases one day!
Aly Harney

Aly's Dad

My dad was diagnosed with grade IV Glioblastoma and after a quick, but fierce, 4-month battle he passed shortly after his 58th birthday. He worked incredibly hard but made sure to find the time most nights to enjoy evenings out on his fishing boat with family. Realizing how quickly you can lose a loved one gave me the motivation to seek work in an environment where I could make real advances in developing treatments or even a cure for patients that receive similar terminal diagnoses.

Corporate Partners

We recognize that drug discovery requires diverse skill sets and expertise to discover and develop new therapeutics. We look for partners that share our philosophy for high scientific integrity and breakthrough science, that complement our skill sets and can take our work to the next level. We enjoy great scientific minds meeting together in a collaborative setting that allows us to accelerate our discovery and development work.
Remix announced a collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
Read More
J & J Innovative Medicine
In 2022, we announced a multi-year, three target, strategic collaboration with Johnson & Johnson Innovation Medicine (Formerly Janssen). This work combines our powerful REMaster drug discovery platform with J&J's disease area expertise in both oncology and immunology.
Read More

Join Us

What we do matters for others.
Current Remixer
See Openings